Question explored with the scientific record
Do statins reduce heart attacks
Yes, statins reduce heart attacks in people who already have heart disease. The benefit is smaller and less certain in people who don't.
For someone who has had a heart attack or has established coronary disease, the evidence is real and uses hard outcomes. A meta-analysis of 14 randomized trials in about 90,000 patients found statins cut heart attack or coronary death by roughly 23% per unit of LDL cholesterol lowered [4]. In the PROVE IT trial, high-dose atorvastatin beat standard pravastatin in women after acute coronary syndrome, with a 25% relative drop in the composite of death, heart attack, and related events [5]. Early statin use after a heart attack was linked to lower one-year death, though that was observational [7].
For primary prevention, the picture is thinner and depends on who you are. In a real-world cohort, statin users had lower heart attack risk overall, but the benefit was largest in people with high genetic risk and smallest in those with low genetic risk [2]. In older adults without known vascular disease, the benefit shrank with age and was not statistically significant past 75 [6]. The costs are real too: high-intensity statins raised new-onset diabetes compared with moderate doses [1], and intensive therapy tripled liver-related adverse events [3].
| Group | Heart attack / event effect | Source |
|---|---|---|
| Established heart disease | ~23% lower MI or coronary death per LDL unit | [4] |
| High genetic risk, primary prevention | HR 0.41 | [2] |
| Low genetic risk, primary prevention | HR 0.67 | [2] |
| High vs moderate intensity | More new diabetes | [1] |
My call: for secondary prevention the benefit is proven and worth it; for primary prevention it is modest, concentrated in higher-risk people, and should be weighed against the diabetes and liver risks. Confidence: moderate, because the primary-prevention trials here are largely observational and the retrieval did not surface the large randomized primary-prevention trials that would settle the low-risk question.
Sources used 7
-
Different diabetogenic effect of statins according to intensity and dose in patients with acute myocardial infarction: a nationwide cohort study
This nationwide cohort study investigates the differential diabetogenic effects of statins based on their intensity and dose in patients with acute myocardial infarction, revealing that high-intensity statin therapy is associated with a higher incidence of new-onset diabetes mel…
DOI: 10.1038/s41598-024-67585-7 -
Polygenic Risk Score and Statin Relative Risk Reduction for Primary Prevention of Myocardial Infarction in a Real‐World Population
In a real-world primary prevention cohort, a CHD polygenic risk score modified statin relative risk reduction for myocardial infarction, with greatest benefit at high PRS and attenuated benefit at low PRS.
DOI: 10.1002/cpt.2715 -
Intensive statin therapy in acute coronary syndromes and stable coronary heart disease: a comparative meta-analysis of randomised controlled trials
Intensive statin therapy reduces all-cause mortality in patients with recent acute coronary syndromes but not in patients with stable coronary heart disease, while reducing MACE and heart failure admissions in both groups.
DOI: 10.1136/hrt.2006.112508 -
The need for wider and appropriate utilization of aspirin and statins in the treatment and prevention of cardiovascular disease
Aspirin and statins, alone and in combination, produce statistically significant and clinically important reductions in myocardial infarction, stroke and cardiovascular death, and both are underutilized in secondary and primary prevention.
DOI: 10.1586/14779072.6.1.95 -
Benefit of Intensive Statin Therapy in Women
In the PROVE IT-TIMI 22 trial, intensive statin therapy reduced the primary composite cardiovascular endpoint in women after acute coronary syndrome (25% relative risk reduction, P=0.04) with no significant sex interaction.
DOI: 10.1161/circoutcomes.110.957720 -
Statin Therapy for Primary and Secondary Prevention in Older Adults
Evidence supports statin therapy for secondary prevention in older adults and for primary prevention in selected high-risk older patients; age alone should not deter statin therapy.
DOI: 10.1007/s11883-024-01257-9 -
Early Statin Treatment Following Acute Myocardial Infarction and 1-Year Survival
This study evaluates the impact of early statin treatment on 1-year mortality in patients who survived an acute myocardial infarction, finding that early initiation of statins significantly reduces mortality risk.
DOI: 10.1001/jama.285.4.430